Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until June 2040—subject to extension to account for time required to fulfill requirements for regulatory approval.
The Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE”, is expected to be issued in the coming months. Moleculin’s novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets).
Walter Klemp, chairman and CEO of Moleculin, commented, “We remain committed to bolstering our global intellectual property portfolio for Annamycin. This Canadian patent further strengthens our current IP portfolio, which includes claims to methods of making our preliposomal Annamycin, in yet another key territory. As we continue to advance our development of Annamycin as a potentially transformative therapeutic candidate for hard-to-treat tumors, building on our global patent protection remains a focus.”
